Inpharma Weekly

, Volume 1379, Issue 1, pp 5–5 | Cite as

Is DOTS-plus worth it for TB in developing countries?

Clinical study


Tuberculosis Hypothetical Cohort Antituberculosis Drug Additional Individual Acceptable Cost 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 2003

Personalised recommendations